|
業務類別
|
Biotechnology |
|
業務概覽
|
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from theUnited States from the sale of its commercial products. |
| 公司地址
| 700 US Highway 202/206, Bridgewater, NJ, USA, 08807 |
| 電話號碼
| +1 908 977-9900 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.insmed.com |
| 員工數量
| 1664 |
| Ms. S. Nicole Schaeffer |
Chief People Strategy Officer |
-- |
01/04/2026 |
| Mr. William H. Lewis, J.D.,M.B.A. |
Chairman of the Board, President and Chief Executive Officer |
美元 854.55K |
01/04/2026 |
| Ms. Sara M. Bonstein |
Chief Financial Officer and Principal Accounting Officer |
美元 583.19K |
01/04/2026 |
| Mr. Roger Adsett |
Chief Operating Officer |
美元 622.59K |
01/04/2026 |
| Dr. Martina Flammer, M.B.A. |
Chief Medical Officer |
美元 634.19K |
01/04/2026 |
| Mr. Michael A. Smith |
Chief Legal Officer |
美元 595.27K |
01/04/2026 |
|
|
| Ms. Carol A. Schafer |
Independent Director |
01/04/2026 |
| Mr. David W.J. McGirr, M.B.A. |
Independent Director |
19/02/2026 |
| Dr. Melvin Sharoky,M.D. |
Independent Director |
01/04/2026 |
| Mr. David R. Brennan |
Lead Independent Director |
01/04/2026 |
| Mr. William H. Lewis, J.D.,M.B.A. |
Chairman of the Board, President and Chief Executive Officer |
01/04/2026 |
| Dr. Clarissa Desjardins, PhD |
Independent Director |
01/04/2026 |
| Mr. Leo Lee |
Independent Director |
01/04/2026 |
| Ms. Elizabeth McKee Anderson, M.B.A. |
Independent Director |
01/04/2026 |
|
|
|
|
